<DOC>
	<DOCNO>NCT00120679</DOCNO>
	<brief_summary>The purpose study validate Patient Satisfaction Questionnaire Anemia Treatment ( PSQ-AT ) non small cell lung cancer patient treat darbepoetin alfa recombinant human erythropoietin ( rHuEPO ) anemia due chemotherapy .</brief_summary>
	<brief_title>Treatment Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Subjects receive multicycle chemotherapy nonsmall cell lung cancer Anemia due chemotherapy ( hgb less equal 11.0 g/dL ) Expected receive great equal 8 additional week chemotherapy part plan treatment Karnofsky Performance Scale ( KPS ) great equal 50 % Adequate renal function Adequate liver function Iron deficiency Unstable cardiac disease Known positive test human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Amgen</keyword>
</DOC>